Evolving Standards in Familial Hypercholesterolemia: Innovations in Diagnosis and Therapeutic Strategies Accreditation Information

Click Here to Listen to the Podcast

PROGRAM OVERVIEW:

Evolving Standards in Familial Hypercholesterolemia: Innovations in Diagnosis and Therapeutic Strategies

ACTIVITY TYPE
Enduring Internet

NLA ID:
2026014

ACTIVITY DATES
Release Date: January 29, 2026
Expiration Date: January 29, 2027

FEE INFORMATION
There is no cost associated with this activity.

TARGET AUDIENCE
This initiative has been designed to address the educational needs of clinicians, including physicians, nurse practitioners (NPs), PAs, and clinical pharmacists. It may also benefit primary care practitioners (PCPs) and other clinicians who are interested or involved in the care of patients with risk factors for cardiovascular disease.

LEARNING OBJECTIVES

• Describe the evolving paradigms in the diagnosis and care of FH, including the rates of heterozygous FH (HeFH) and homozygous FH (HoFH), and the low rates of screening in children.
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
• Discuss the expanding role of genetic testing in FH, including its use for risk stratification and its potential to predict a patient's response to therapies such as PCSK9 inhibitors.
• Evaluate and apply various lipid-lowering strategies, including combination approaches, to optimize treatment for FH patients.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form.   Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. Please claim credit by January 30, 2027.

COMMERCIAL SUPPORT
This activity is supported by independent educational grants from Esperion and Merck.

CREDIT DESIGNATION
CME/CE credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by the National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacist Accreditation Statement

Universal Activity Number JA0007192-0000-26-013-H01-P
This Activity has been approved for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 0.75 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

For Dietitians: Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities / materials by CDR.

DISCLOSURE INFORMATION
FACULTY, PLANNERS & REVIEWERS

Zahid Ahmad, MD, FNLA
Principal Investigator: Ionis
Adjudication Committee Chair: Amyrt
Contracted Research: National Institute of Health, U.S. Department of Defense

Dave L. Dixon, PharmD, FACC, FAHA, FCCP, FNLA, BCACP, CLS
Principal Investigator: Boehringer Ingelheim, Inc.

Joseph Saseen, PharmD, MNLA, BCPS, BCACP, CLS
Committee Member: Amgen

Anne Carol Goldberg, MD, FACP, FAHA, MNLA
Principal Investigator: Amgen, Arrowhead, Ionis, Marea, New Amsterdam, Novartis, Esperion, 89Bio, Sanofi
National Lead Investigator: Ionis
Committee Member: Eli Lilly, New Amsterdam

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Click Here to Complete a Program Evaluation and Claim Credit